REFERENCES
- Office of National Drug Control Policy, http://www.whitehousedrugpolicy.gov/publications/policy/03ndcs/table21.html National Drug Control Strategy, February 2002. Available at. Accessed January 27, 2003
- SAMSHA: The National Survey on Drug Use and Health. 2006, http://oas.samhsa.gov/nsduh/2k6nsduh/2k6results.cfm accessed March 3, 2008
- http://monitoringthefuture.org/pubs/monographs/voll2006.pdf Monitoring the Future, accessed March 3, 2008
- Stephens R S, Roffman R A, Simpson E E. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol 1994; 62: 92–99
- Stephens R S, Roffman R A, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 2000; 68: 898–908
- Budney A J, Higgins S T, Radonovich K J, Novy P L. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 2000; 68: 1051–1061
- Dennis M, Titus J C, Diamond G, et al. The Cannabis Youth Treatment (CYT) experiment: rationale, study design and analysis plans. Addiction 2002; 97(Suppl. 1)16–34
- Diamond G, Godley S H, Liddle H A, et al. Five outpatient treatment models for adolescent marijuana use: a description of the Cannabis Youth Treatment Interventions. Addiction 2002; 97(Suppl. 1)70–83
- French M T, Roebuck M C, Dennis M L, et al. The economic cost of outpatient marijuana treatment for adolescents: findings from a multi-site field experiment. Addiction 2002; 97(Suppl. 1)84–97
- Dennis M, Godley S H, Diamond G, et al. The Cannabis Youth Treatment (CYT) study: main findings from two randomized trials. J Subst Abuse Treat 2004; 27: 197–213
- Stephens R S, Babor T F, Kadden R, Miller M. The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction 2002; 97(Suppl. 1)109–124
- Steinberg K L, Roffman R A, Carroll K M, et al. Tailoring cannabis dependence treatment for a diverse population. Addiction 2002; 97(Suppl. 1)135–142
- Cornelius J R, Salloum I M, Haskett R F, et al. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav 1999; 24: 111–114
- Levin F R, McDowell D, Evans S M, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004; 13: 21–32
- Kouri E M, Pope H G, Jr. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 2000; 8: 483–492
- Wiesbeck G A, Schuckit M A, Kalmijn J A, Tipp J E, Bucholz K K, Smith T L. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 1996; 91: 1469–1478
- Mendelson J H, Mello N K, Lex B W, Bavli S. Marijuana withdrawal syndrome in a woman. Am J Psychiatry 1984; 141: 1289–1290
- Haney M, Ward A S, Comer S D, Foltin R W, Fischman M W. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 1999; 141: 395–404
- Hart C L, Haney M, Ward A S, Fischman M W, Foltin R W. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend 2002; 67: 301–309
- Haney M, Hart C L, Vosburg S K, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004; 29: 158–170
- Budney A J, Moore B A, Vandrey R G, Hughes J R. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003; 112: 393–402
- Haney M, Ward A S, Comer S D, Hart C L, Foltin R W, Fischman M W. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl) 2001; 155: 171–179
- Haney M, Hart C L, Ward A S, Foltin R W. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl) 2003; 165: 157–165
- Budney A J, Vandrey R G, Hughes J R, Moore B A, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007; 86: 22–29
- Chait L D, Zacny J P. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology (Berl) 1992; 107: 255–262
- Kirk J M, Doty P, De Wit H. Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 59: 287–293
- Calhoun S R, Galloway G P, Smith D E. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998; 30: 187–196
- Donovan S J, Stewart J W, Nunes E V, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000; 157: 818–820